Guardant Health (GH) Tops Q1 EPS by 26c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
April 30, 2025 4:05 PM EDTRevenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data
Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20%
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights
For the three-month period ended March 31, 2025, as compared to the same period of 2024:
Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of... More